Paper Search Results


AuthorId: 145811137
Limit: 10
Sort by: score
Embedding: s2_recommendations
IP address: 18.116.15.22
Freq flyer: False

authorId(s): 145811137
Author(s): E. Acosta
scorecitationCountPaperAuthorsyearMore like thisCompare & ContrastProNE-sSciNCLSpecterGNN
701
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
D. Haas, H. Ribaudo, ..., E. Acosta
2004
595
Valganciclovir for symptomatic congenital cytomegalovirus disease.
D. Kimberlin, P. Jester, ..., R. Whitley
2015
529
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
R. Gulick, H. Ribaudo, ..., D. Kuritzkes
2004
326
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
Lin Shen, Susan Peterson, ..., R. Siliciano
2008
284
Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals
D. Clifford, S. Evans, ..., R. Gulick
2005
256
Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.
D. Kimberlin, E. Acosta, ..., R. Whitley
2008
246
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
H. Ribaudo, D. Haas, ..., E. Acosta
2006
231
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
R. Gulick, H. Ribaudo, ..., D. Kuritzkes
2006
226
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
D. McMahon, J. Jones, ..., F. Maldarelli
2010
196
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.
D. Kuritzkes, C. Lalama, ..., R. Gulick
2008

Help Bulk Download
GitHub Final Report (YouTube)
JSALT-2023 Contact us (by email)
BETA Version